Condition 1: Tropical spastic paraplegia. Condition 2: Spastic hemiplegia. Condition 3: Multiple sclerosis. Condition 4: Neuromyelitis optica. Condition 5: Hypoxic ischemic encephalopathy. Condition 6: Spondylolysis cervical. Tropical spastic paraplegia Spastic hemiplegia Multiple sclerosis Neuromyelitis optica [Devic] Hypoxic ischemic encephalopathy [HIE], unspecified Spondylolysis, cervical region
Conditions
Interventions
Intervention 1: Intervention group:25 people in the intervention group who have spasticity disorder are treated topically with standard Aral kharatin oil made in Iran for 3 months. First, the limb wit
Sponsors
Kerman University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Existence of spasticity disorder
Exclusion criteria
Exclusion criteria: Sensitivity to kharatin oil
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Paralysis performance score in modified ashworth scale questionnair. Timepoint: At the beginning of the study and 3 months after starting to use kharatin oil and paraffin. Method of measurement: modified ashworth scale questionnair. | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life score. Timepoint: At the beginning of the study and 3 months after consuming kharatin oil and paraffin. Method of measurement: World Health Organization Quality of Life Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMona Arab
Kerman University of Medical Sciences
Outcome results
None listed